Menoux I, Antoni D, Mazzara C, Labani A, Charloux A, Quoix E, Falcoz P-E, Truntzer P, Noël G
Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France.
Department of Radiotherapy, Paul Strauss Center, 3, rue de la Porte-de-l'Hôpital, BP 42, 67065 Strasbourg cedex, France; CNRS, IPHC UMR 7178, université de Strasbourg, Centre Paul-Strauss, institut régional de cancérologie, UNICANCER, 67000 Strasbourg, France.
Cancer Radiother. 2020 Apr;24(2):120-127. doi: 10.1016/j.canrad.2019.11.003. Epub 2020 Mar 12.
The main complication after hypofractionated radiotherapy for lung carcinoma is radiation-induced lung toxicity, which can be divided into radiation pneumonitis (acute toxicity, occurring within 6 months) and lung fibrosis (late toxicity, occurring after 6 months). The literature describes several predictive factors related to the patient, to the tumor (volume, central location), to the dosimetry and to biological factors.
This study is a retrospective analysis of 90 patients treated with stereotactic body irradiation for stage I non-small-cell lung carcinoma between December 2010 and May 2015.
Radiation pneumonitis was observed in 61.5% of the patients who were mainly asymptomatic (34%). Chronic obstructive pulmonary disease was not predictive of radiation pneumonitis, whereas active smoking was protective. Centrally located tumors were not more likely to result in this complication if the radiation schedule utilized adapted fractionation. In our study, no predictive factor was identified. Whereas the mean lung dose was a predictive factor in 3D radiotherapy, the lung volume irradiated at high doses seemed to be involved in the pathogenesis after hypofractionated radiotherapy.
The discovery of predictive factors for radiation pneumonitis is difficult due to the rarity of this complication, especially with an 8×7.5Gy schedule. Radiation pneumonitis seems to be correlated with the volume irradiated at high doses, which is in contrast to the known knowledge about the organs in parallel. This finding leads us to raise the hypothesis that vessel damage, organs in series, occurring during hypofractionated radiotherapy could be responsible for this toxicity.
肺癌大分割放疗后的主要并发症是放射性肺损伤,可分为放射性肺炎(急性毒性,发生在6个月内)和肺纤维化(晚期毒性,发生在6个月后)。文献描述了一些与患者、肿瘤(体积、中心位置)、剂量学和生物学因素相关的预测因素。
本研究是一项对2010年12月至2015年5月期间接受立体定向体部放疗的90例I期非小细胞肺癌患者的回顾性分析。
61.5%的患者出现放射性肺炎,其中大多数无症状(34%)。慢性阻塞性肺疾病不是放射性肺炎的预测因素,而当前吸烟具有保护作用。如果放疗方案采用适形分割,中心型肿瘤并不更易导致这种并发症。在我们的研究中,未发现预测因素。虽然平均肺剂量在三维放疗中是一个预测因素,但在大分割放疗后,高剂量照射的肺体积似乎参与了发病机制。
由于这种并发症罕见,尤其是在8×7.5Gy方案下,很难发现放射性肺炎的预测因素。放射性肺炎似乎与高剂量照射的体积相关,这与关于并行器官的已知知识相反。这一发现使我们提出假设,即在大分割放疗期间发生的串联器官血管损伤可能是这种毒性的原因。